Wall Street analysts expect ReWalk Robotics Ltd (NASDAQ:RWLK) to report sales of $1.70 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for ReWalk Robotics’ earnings, with estimates ranging from $1.60 million to $1.80 million. ReWalk Robotics posted sales of $1.59 million during the same quarter last year, which would indicate a positive year over year growth rate of 6.9%. The company is scheduled to report its next earnings report on Friday, February 16th.

On average, analysts expect that ReWalk Robotics will report full year sales of $1.70 million for the current fiscal year, with estimates ranging from $7.76 million to $8.80 million. For the next financial year, analysts anticipate that the firm will post sales of $11.86 million per share, with estimates ranging from $11.30 million to $12.42 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that follow ReWalk Robotics.

ReWalk Robotics (NASDAQ:RWLK) last announced its quarterly earnings results on Thursday, November 2nd. The medical device company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.10. The firm had revenue of $1.70 million for the quarter, compared to the consensus estimate of $1.63 million. ReWalk Robotics had a negative return on equity of 568.25% and a negative net margin of 346.14%. The company’s quarterly revenue was up 21.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.62) earnings per share.

A number of analysts recently commented on RWLK shares. Jefferies Group LLC reduced their price objective on ReWalk Robotics from $8.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, November 3rd. Canaccord Genuity reduced their price objective on ReWalk Robotics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, August 4th. Oppenheimer Holdings, Inc. set a $4.00 price objective on ReWalk Robotics and gave the company a “buy” rating in a research report on Friday, August 4th. Finally, Zacks Investment Research upgraded ReWalk Robotics from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research report on Thursday. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $3.00.

TRADEMARK VIOLATION WARNING: “Zacks: Analysts Anticipate ReWalk Robotics Ltd (RWLK) Will Announce Quarterly Sales of $1.70 Million” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/11/11/zacks-analysts-anticipate-rewalk-robotics-ltd-rwlk-will-announce-quarterly-sales-of-1-70-million.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its stake in shares of ReWalk Robotics by 61.7% in the first quarter. Renaissance Technologies LLC now owns 78,600 shares of the medical device company’s stock worth $165,000 after acquiring an additional 30,000 shares during the period. Advisor Group Inc. boosted its stake in shares of ReWalk Robotics by 1,495.6% in the third quarter. Advisor Group Inc. now owns 181,900 shares of the medical device company’s stock worth $264,000 after acquiring an additional 170,500 shares during the period. Finally, Essex Investment Management Co. LLC boosted its stake in shares of ReWalk Robotics by 328.7% in the third quarter. Essex Investment Management Co. LLC now owns 156,981 shares of the medical device company’s stock worth $228,000 after acquiring an additional 120,362 shares during the period. 3.81% of the stock is owned by hedge funds and other institutional investors.

ReWalk Robotics (NASDAQ RWLK) remained flat at $$1.37 during trading on Wednesday. 110,700 shares of the company’s stock were exchanged, compared to its average volume of 346,555. The company has a current ratio of 2.02, a quick ratio of 1.65 and a debt-to-equity ratio of 7.46. ReWalk Robotics has a 52-week low of $1.10 and a 52-week high of $3.60.

About ReWalk Robotics

ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement.

Get a free copy of the Zacks research report on ReWalk Robotics (RWLK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for ReWalk Robotics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics Ltd and related stocks with our FREE daily email newsletter.